Lipid H5T5|pan-CAR ionizable lipid |DC Chemicals

Cas No.:	3097464-85-9
Chemical Name:	Lipid H5T5
Synonyms:	LipidH5T5;Lipid-H5T5
SMILES:	CC(C)=CCC/C(C)=C/CC/C(C)=C/COC(=O)CCN(CCCN(C)C)CCCN(CCC(=O)OC/C=C(\C)CC/C=C(\C)CCC=C(C)C)CCC(=O)OC/C=C(\C)CC/C=C(\C)CCC=C(C)C
Formula:	C₆₂H₁₀₅O₆N₃
M.Wt:	988.54
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	Lipid nanoparticle–mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy-Qimeng Yin, Xue Liang, Chenchen Zhang etl. PNAS 123 (8) e2509698123

Cat. No.	Product name	Field of application
DC60925	Lipid H5T5	H5T5 is a leading ionizable lipid nanoparticle (LNP) formulation optimized for in vivomRNA delivery, featuring a pKa of 6.51, a size of ~154 nm, and a narrow polydispersity index (PDI) of 0.05. It demonstrated superior in vitromRNA transfection efficiency in primary immune cells, such as bone marrow-derived macrophages. Following intravenous administration, H5T5 exhibits precise organotropism, predominantly targeting the spleen and bone marrow, where it effectively delivers mRNA to a broad spectrum of immune cells, including macrophages, dendritic cells, T cells, B cells, and NK cells. This capability enables its core application: the in vivogeneration of "pan-CAR" immune cells. When loaded with anti-HER2 CAR mRNA, the H5T5-based therapy achieved potent tumor regression and prolonged survival in multiple solid tumor models. Preliminary safety assessments indicated a manageable cytokine profile and no significant organ toxicity, positioning it as a promising platform for in vivocell engineering.